These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29280411)

  • 1. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
    Pollack SM
    Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
    Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
    Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
    Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
    J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
    Chawla SP; Van Tine BA; Pollack SM; Ganjoo KN; Elias AD; Riedel RF; Attia S; Choy E; Okuno SH; Agulnik M; von Mehren M; Livingston MB; Keedy VL; Verschraegen CF; Philip T; Bohac GC; Yurasov S; Yakovich A; Lu H; Chen M; Maki RG
    J Clin Oncol; 2022 Apr; 40(12):1291-1300. PubMed ID: 34260265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
    Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
    Somaiah N; Block MS; Kim JW; Shapiro GI; Do KT; Hwu P; Eder JP; Jones RL; Lu H; Ter Meulen JH; Bohac C; Chen M; Hsu FJ; Gnjatic S; Pollack SM
    Clin Cancer Res; 2019 Oct; 25(19):5808-5817. PubMed ID: 31227504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
    J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.
    Albershardt TC; Campbell DJ; Parsons AJ; Slough MM; Ter Meulen J; Berglund P
    Mol Ther Oncolytics; 2016; 3():16010. PubMed ID: 27626061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
    Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
    Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
    Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
    J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
    Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A
    Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
    Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
    J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.